ADITXT Raises ATM Offering to $20M, Schedules January Vote on Preferred Stock

Company Overview

ADITXT INC (NASDAQ: ADTX), founded in 2017 and headquartered in Richmond, Virginia, operates as a publicly traded social innovation platform focused on discovering, developing, and deploying healthcare innovations. The company’s core activities include immune monitoring and modulation, precision diagnostics, and the development of vaccines and antivirals. ADITXT’s mission emphasizes the utilization of social capital to address autoimmune disorders, infectious diseases, cancer, and other health challenges.

Corporate Structure

ADITXT employs approximately 51–200 individuals and is led by Co-Founder and CEO Amro Albanna. In December 2025, the company announced the appointment of Christopher Porcelli as General Counsel and Chief People Officer. ADITXT’s leadership team has experience in start-up biotech ventures, clinical trial design, biopharmaceutical marketing, and public company management. Subsidiaries include Pearsanta, Inc., which focuses on platforms for early disease detection.

Healthcare Innovation by Tom Claes

Developments and News

On April 2, 2024, ADITXT completed the acquisition of Appili Therapeutics Inc. under a definitive arrangement agreement. Appili shareholders received 0.002745004 shares of ADITXT common stock plus US$0.0467 in cash per Appili share, representing a premium based on the trading price prior to the execution of the agreement.
In May 2025, Pearsanta received Institutional Review Board (IRB) approval to initiate a prospective study of its Mitomic® Endometriosis Test, starting with an initial 104 subjects and planning for an expansion to 1,000 subjects.
On December 12, 2025, ADITXT amended its at-the-market (ATM) offering prospectus (Rule 424(b)(5)), increasing the maximum aggregate gross sales price of its common stock from US$11.84 million to US$20.0 million. As of December 12, 2025, the company had sold 1,370,607 shares under the prior prospectus, yielding US$17.77 million in gross proceeds.
A special meeting of stockholders is scheduled for January 30, 2026, to consider proposals for approving issuances related to Series A-1 Convertible Preferred Stock (issued December 2023) and Series C-1 Convertible Preferred Stock (issued May and August 2024), as disclosed in the definitive proxy statement filed on December 16, 2025.

Financial and Strategic Analysis

On December 12, 2025, ADITXT’s common stock last traded at US$2.24 per share. Earlier quotes indicate a price of US$1.90 with a 33.80% intraday gain and volume of 3,440,326 shares on the NASDAQ exchange. As of November 28, 2025, key trailing twelve-month metrics included:

• Revenue: US$5.95 thousand
• Net loss attributable to common shareholders: US$42.24 million
• Diluted EPS: –US$829.58
• Return on assets: –61.7%
• Price/Sales ratio: 32.55
• Market capitalization: approximately US$2.13 million
• Enterprise value: US$7.64 million
• Total cash: US$163,040
• Levered free cash flow: –US$9.75 million

ADITXT has focused on acquisitions (notably Appili Therapeutics and Pearsanta’s technology platforms) and equity financing (ATM offering) to build its pipeline while addressing liquidity needs. The upcoming shareholder vote on preferred stock issuances may influence the company’s capital structure.

Market Position and Industry Context

ADITXT operates within the healthcare and diagnostics sector, concentrating on immune profiling, precision diagnostics, and antivirals. The company currently generates minimal recurring revenue and invests significantly in research and development, which is typical of early-stage companies in the biotechnology space. Its valuation metrics indicate high growth expectations among small-cap biotech peers, with a notable enterprise-value-to-revenue ratio. The company’s strategy centers on clinical validation of diagnostic tests and the integration of acquired technologies aimed at commercialization.

TL;DR

A special stockholder meeting is set for January 30, 2026, to approve preferred-stock issuances. On December 12, 2025, the ATM offering limit was raised to US$20 million, following US$17.77 million raised under the prior prospectus. Pearsanta’s endometriosis diagnostic study commenced enrollment in May 2025. Moving forward, ADITXT will balance clinical development milestones with equity financing to support its immunology and diagnostics platform.